On 6th April 2022, METiS Pharmaceuticals (METiS, hereinafter referred to as "METiS"), a leading company in the research and development of AI pharmaceutical preparations, officially announced the completion of two consecutive rounds of A+B financing. PICC Capital participated in the A round of financing as the lead investor, and continued to increase its stake in the B round. Co-investors include Sequoia Capital, Wuyuan Capital, CMB International, Lightspeed China, Monolith and other well-known institutions. The two rounds of financing totaled US$150 million, which would further promote METiS to improve the research pipeline and AI+HTS platform, and deeply build a new form of pharmaceutical enterprise under the intelligent revolution.
Founded at the end of 2019, Metis is the world's first technology company that uses artificial intelligence to drive the development of pharmaceutical preparations. The team combines technologies such as high-throughput preparation platforms and artificial intelligence computing to provide pharmaceutical companies with rapid and accurate research and development of intelligent preparations.
PICC Health Care Fund is an insurance private equity investment fund focusing on medical and health managed by PICC Capital Equity Investment Co., Ltd., a subsidiary of PICC Capital, with a scale of 3 billion yuan in the first phase. PICC Capital Equity Investment Co., Ltd. practices its philosophy and understands that the value of innovation should from in-depth research, forward-looking vision and clinical practical needs, with the aim of a better life.
Acting as the legal counsel of PICC, Llinks was involved in the negotiation of the investment structure and the draft of the transaction documents, protecting the interests of PICC.
Llinks Team:
Partners: Selena She, Colin Shi
Associate: Aurora Zhang
